Shamin Rezaei

STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response.

M. Ghollasi, M. Hashemi, S. Samarghandian, 2022, Pharmacological research.

Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: Tumorigenesis, chemoresistance, and radioresistance.

K. Rangappa, M. Hashemi, C. D. Mohan, 2022, Pharmacological research.

LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions.

M. Hashemi, S. Samarghandian, Sepideh Mirzaei, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Targeting PI3K/Akt signaling in prostate cancer therapy

M. Hashemi, S. Samarghandian, Sepideh Mirzaei, 2022, Journal of Cell Communication and Signaling.

siRNA and targeted delivery systems in breast cancer therapy

M. Hashemi, S. Samarghandian, Sepideh Mirzaei, 2022, Clinical and Translational Oncology.

Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.

M. Hashemi, K. Hushmandi, M. Entezari, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

SOX2 function in cancers: Association with growth, invasion, stemness and therapy response.

M. Hashemi, S. Samarghandian, Sepideh Mirzaei, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

The pharmacological and biological importance of EZH2 signaling in lung cancer.

M. Hashemi, S. Samarghandian, Sepideh Mirzaei, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

miRNAs as short non-coding RNAs in regulating doxorubicin resistance

Sepideh Mirzaei, M. Entezari, A. Taheriazam, 2023, Journal of Cell Communication and Signaling.